Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MITO 27: Pembrolizumab in Recurrent Ovarian Cancer
NCT04375956Phase 2Unknown
- Sponsor
- Policlinico Gemelli
- Start
- Apr 2021
- Primary completion
- Jun 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal carcinoma (PPC), sponsored by Policlinico Gemelli. Primary endpoint: Overall Survival at 44 months. Status: unknown.
02
Drugs
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT04375956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04375956.